141 related articles for article (PubMed ID: 38413097)
1. Efficacy and safety of tildrakizumab in elderly patients: real-world multicenter study (ESTER - study).
Orsini D; Caldarola G; Dattola A; Campione E; Bernardini N; Frascione P; De Simone C; Richetta AG; Galluzzo M; Skroza N; Assorgi C; Amore E; Falco GM; Gaeta Shumak R; Artosi F; Maretti G; Potenza C; Bianchi L; Pellacani G; Peris K; Bonifati C; Graceffa D
J Dermatolog Treat; 2024 Dec; 35(1):2319304. PubMed ID: 38413097
[No Abstract] [Full Text] [Related]
2. Real-world practice indirect comparison between guselkumab, risankizumab, and tildrakizumab: results from an Italian 28-week retrospective study.
Megna M; Tommasino N; Potestio L; Battista T; Ruggiero A; Noto M; Fabbrocini G; Genco L
J Dermatolog Treat; 2022 Sep; 33(6):2813-2820. PubMed ID: 35603992
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of Tildrakizumab for the Treatment of Difficult-to-Treat Areas: Scalp, Nail, Palmoplantar and Genital Psoriasis.
Galluzzo M; Talamonti M; Cioni A; Maffei V; Shumak RG; Tofani L; Bianchi L; Campione E
J Clin Med; 2022 May; 11(9):. PubMed ID: 35566756
[TBL] [Abstract][Full Text] [Related]
4. Anti-interleukin-23 for psoriasis in elderly patients: guselkumab, risankizumab and tildrakizumab in real-world practice.
Ruggiero A; Fabbrocini G; Cinelli E; Ocampo Garza SS; Camela E; Megna M
Clin Exp Dermatol; 2022 Mar; 47(3):561-567. PubMed ID: 34642965
[TBL] [Abstract][Full Text] [Related]
5. Comparative effectiveness of tildrakizumab 200 mg versus tildrakizumab 100 mg in psoriatic patients with high disease burden or above 90 kg of body weight: a 16-week multicenter retrospective study - IL PSO (Italian landscape psoriasis).
Gargiulo L; Ibba L; Cascio Ingurgio R; Malagoli P; Amoruso F; Balato A; Bardazzi F; Brianti P; Brunasso G; Burlando M; Cagni AE; Caproni M; Carrera CG; Carugno A; Caudullo F; Cuccia A; Dapavo P; Di Brizzi EV; Dini V; Gaiani FM; Gisondi P; Guarneri C; Lasagni C; Licata G; Loconsole F; Marzano AV; Megna M; Mercuri SR; Musumeci ML; Orsini D; Ribero S; Ruffo Di Calabria V; Satolli F; Strippoli D; Travaglini M; Trovato E; Venturini M; Zichichi L; Valenti M; Costanzo A; Narcisi A
J Dermatolog Treat; 2024 Dec; 35(1):2350760. PubMed ID: 38714323
[TBL] [Abstract][Full Text] [Related]
6. Tildrakizumab in moderate-to-severe plaque psoriasis: A multicenter, retrospective, real-life study.
Caldarola G; Galluzzo M; Bernardini N; Calabrese L; Grimaldi M; Moretta G; Pagnanelli G; Shumak RG; Talamonti M; Tofani L; Pallotta S; Peris K; Potenza C; De Simone C; Campione E
Dermatol Ther; 2022 Jun; 35(6):e15488. PubMed ID: 35384168
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of tildrakizumab in Japanese patients with moderate to severe plaque psoriasis: Results from a 64-week phase 3 study (reSURFACE 1).
Igarashi A; Nakagawa H; Morita A; Okubo Y; Sano S; Imafuku S; Tada Y; Honma M; Mendelsohn AM; Kawamura M; Ohtsuki M
J Dermatol; 2021 Jun; 48(6):853-863. PubMed ID: 33630387
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of tildrakizumab for moderate-to-severe plaque psoriasis: pooled analysis of three randomized controlled trials at weeks 12 and 28.
Papp KA; Reich K; Blauvelt A; Kimball AB; Gooderham M; Tyring SK; Sinclair R; Thaci D; Li Q; Cichanowitz N; Green S; La Rosa C
J Eur Acad Dermatol Venereol; 2019 Jun; 33(6):1098-1106. PubMed ID: 30838709
[TBL] [Abstract][Full Text] [Related]
9. Long-term efficacy and safety of tildrakizumab in Japanese patients with moderate to severe plaque psoriasis: Results from a 5-year extension of a phase 3 study (reSURFACE 1).
Imafuku S; Nakagawa H; Igarashi A; Morita A; Okubo Y; Sano S; Tada Y; Nemoto O; Rozzo SJ; Kawamura M; Ohtsuki M
J Dermatol; 2021 Jun; 48(6):844-852. PubMed ID: 33523513
[TBL] [Abstract][Full Text] [Related]
10. Real-World Effectiveness and Safety of Tildrakizumab in Patients With Moderate-to-Severe Psoriasis: Week 28 Interim Analysis of a Phase 4 Study.
Heim J; Vasquez JG; Schenkel B; Bhatia N
J Drugs Dermatol; 2023 Aug; 22(8):754-760. PubMed ID: 37556515
[TBL] [Abstract][Full Text] [Related]
11. Tildrakizumab in Combination With Topical Halcinonide 0.1% Ointment for Treating Moderate to Severe Plaque Psoriasis.
Bagel J; Novak K; Nelson E
J Drugs Dermatol; 2023 Aug; 22(8):766-772. PubMed ID: 37556520
[TBL] [Abstract][Full Text] [Related]
12. Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials.
Reich K; Papp KA; Blauvelt A; Tyring SK; Sinclair R; Thaçi D; Nograles K; Mehta A; Cichanowitz N; Li Q; Liu K; La Rosa C; Green S; Kimball AB
Lancet; 2017 Jul; 390(10091):276-288. PubMed ID: 28596043
[TBL] [Abstract][Full Text] [Related]
13. Psoriasis treat to target: defining outcomes in psoriasis using data from a real-world, population-based cohort study (the British Association of Dermatologists Biologics and Immunomodulators Register, BADBIR).
Mahil SK; Wilson N; Dand N; Reynolds NJ; Griffiths CEM; Emsley R; Marsden A; Evans I; Warren RB; Stocken D; Barker JN; Burden AD; Smith CH;
Br J Dermatol; 2020 May; 182(5):1158-1166. PubMed ID: 31286471
[TBL] [Abstract][Full Text] [Related]
14. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
Sbidian E; Chaimani A; Afach S; Doney L; Dressler C; Hua C; Mazaud C; Phan C; Hughes C; Riddle D; Naldi L; Garcia-Doval I; Le Cleach L
Cochrane Database Syst Rev; 2020 Jan; 1(1):CD011535. PubMed ID: 31917873
[TBL] [Abstract][Full Text] [Related]
15. Tildrakizumab for the Treatment of Moderate-to-Severe Psoriasis: Results from 52 Weeks Real-Life Retrospective Study.
Ruggiero A; Fabbrocicni G; Cacciapuoti S; Potestio L; Gallo L; Megna M
Clin Cosmet Investig Dermatol; 2023; 16():529-536. PubMed ID: 36873660
[TBL] [Abstract][Full Text] [Related]
16. Tildrakizumab for the treatment of psoriasis.
Sinclair R; Thirthar Palanivelu V
Expert Rev Clin Immunol; 2019 Jan; 15(1):5-12. PubMed ID: 30394141
[No Abstract] [Full Text] [Related]
17. Real-world effectiveness and safety of tildrakizumab in long-term treatment of plaque psoriasis: Results from the non-interventional, prospective, multicentre study TILOT.
Tsianakas A; Schwichtenberg U; Pierchalla P; Hinz T; Diemert S; Korge B
J Eur Acad Dermatol Venereol; 2023 Jan; 37(1):85-92. PubMed ID: 36066998
[TBL] [Abstract][Full Text] [Related]
18. Psoriasis patients' characteristics associated with high PASI response to tildrakizumab: an international dual center study.
Burlando M; Maul JT; Salvi I; Simic D; Cozzani E; Ak M; Birkenmaier I; Parodi A
Eur Rev Med Pharmacol Sci; 2022 Sep; 26(18):6772-6776. PubMed ID: 36196725
[TBL] [Abstract][Full Text] [Related]
19. Real-world evidence from the non-interventional, prospective, German multicentre PERSIST study of patients with psoriasis after 1 year of treatment with guselkumab.
Gerdes S; Asadullah K; Hoffmann M; Korge B; Mortazawi D; Wegner S; Personke Y; Gomez M; Sticherling M
J Eur Acad Dermatol Venereol; 2022 Sep; 36(9):1568-1577. PubMed ID: 35569014
[TBL] [Abstract][Full Text] [Related]
20. Long-term efficacy and safety of tildrakizumab for moderate-to-severe psoriasis: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2) through 148 weeks.
Reich K; Warren RB; Iversen L; Puig L; Pau-Charles I; Igarashi A; Ohtsuki M; Falqués M; Harmut M; Rozzo S; Lebwohl MG; Cantrell W; Blauvelt A; Thaçi D
Br J Dermatol; 2020 Mar; 182(3):605-617. PubMed ID: 31218661
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
